Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $232.28 +1.11%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $8.13, $2.20 better than the analyst estimate of $5.93. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees Q4 2025 revenue of $4.175-4.275 billion, versus the consensus of $4.221 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
